# US 8,772,031 B2 · Composition for reprogramming somatic cells to generate induced pluripotent stem cells, comprising Oct4 in combination with Bmi1 or its upstream regulator, and method for generating induced pluripotent stem cells using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,772,031 B2
- Document ID: US8772031B2
- Status: Granted
- Kind: B2
- Application number: 13/890,896
- Filed: 2013-05-09
- Published: 2013-10-24
- Granted: 2014-07-08
- Earliest claimed: 2009-12-30
- Assignees: Korea University Research and Business Foundation
- Applicants: Korea University Research and Business Foundation
- Inventors: Seungkwon You; Jai-Hee Moon; Jun Sung Kim; Byung Sun Yoon; Jung Han Lee; Eun Kyoung Jun; June Seok Heo
- Web page: https://patentgrep.com/patent/US8772031B2

## CPC

- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 2501/41: Hedgehog proteins; Cyclopamine (inhibitor)
- C12N 2501/60: Transcription factors
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a composition for reprogramming somatic cells to generate embryonic stem cell-like cells, comprising: a) a Bmi1 (B cell-specific Moloney murine leukemia virus integration site 1) protein or a nucleic acid molecule coding for Bmi1; and b) an Oct4 protein or a nucleic acid molecule coding for Oct4. Also, a method is provided for reprogramming somatic cells to generate embryonic stem cell-like cells using the composition. In addition to reducing the number of the genetic factors conventionally needed, the composition and method allow the generation of pluripotent embryonic stem cell-like cells which have high potential in the cell therapy of various diseases.

## Claims

### Claim 1

A method for reprogramming somatic cells to generate induced mouse pluripotent stem cells, comprising steps of:
(i) simultaneously treating mouse fibroblasts with a Shh (Sonic hedgehog signaling) protein, oxysterol, purmorphamine, and a packaging cell expressing a vector encoding Oct4, wherein the treated fibroblasts are cultured in a neural stem cell media containing DMEM/F12, B27, N2, bFGF, and EGF
(ii) culturing the cells produced from step (i) in an embryonic stem cell culture conditions including DMEM, LIF, and a feeder layer;
thereby producing induced mouse pluripotent stem cells.